XSOLLA
7.8.2024 15:39:31 CEST | Business Wire | Press release
Xsolla, a global video game commerce company, will attend and present at the Devcom Developer Conference and Gamescom 2024, the world's largest computer and video games event, taking place from August 19th to August 23rd in Cologne, Germany, EU. These events will provide the ideal platform for Xsolla to showcase its cutting-edge solutions, designed to create seamless Cross-Play and Cross-Pay experiences for game developers and players. Their powerful new offerings include Xsolla Backend, Xsolla Mobile SDK, and Xsolla Instant Solutions, featuring Instant Web Shop, Instant Game Sales, Instant Launcher, and Instant Cloud Gaming.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240807882430/en/
(Graphic: Xsolla)
Xsolla Backend
Xsolla Backend offers developers a scalable and affordable solution to enhance game functionality and player engagement across all technology platforms. This includes a built-in launcher and website, efficient matchmaking, over 20 game management systems, and robust cross-play and multiplayer functionalities.
Xsolla Mobile SDK
Xsolla's Mobile SDK is designed to enhance revenue streams for mobile game developers by enabling seamless in-game payments and supporting out-of-store builds and in-store processing for in-app purchases (IAP). With compatibility across platforms like AltStore and Epic Games Store Mobile, the SDK also empowers developers to offer a modern payment experience that complies with iOS and Android regulations. It provides global coverage with over 700 payment methods, making it easier than ever for developers to monetize their games and reach a wider audience.
Xsolla Instant Solutions
Xsolla expanded the Instant Web Shop to include offers of Instant Game Sales, Instant Launcher, and Instant Cloud Gaming to enable faster integration and revenue generation for video game developers. Instant Web Shop enables quick setup of online stores with features like personalization and promotions to enhance user engagement and revenue. Instant Game Sales facilitates direct-to-consumer sales by importing content from platforms like Steam and Epic Game Store. Instant Launcher provides a pre-designed app for direct game distribution, supporting various release stages while reducing costs and promoting cross-engagement. Instant Cloud Gaming allows developers to launch a branded cloud gaming platform quickly, offering pre-launch testing and global reach to expand revenue opportunities.
“We’re excited to be back at Gamescom this year and showcase our latest solutions to the global gaming community,” said David Stelzer, President of Xsolla. “Our solutions are crafted to empower developers and publishers with the tools they need to succeed in today’s dynamic landscape. We invite all attendees to visit our booth and see firsthand how Xsolla can elevate their game development and business operations.”
Attendees can visit Xsolla at Hall 2.2, Booth #A-030 B-037, where live demonstrations of Xsolla’s Payments and Web Shop and these latest solution releases will be held throughout the event. Xsolla’s team of experts will be available to answer questions, provide insights, and discuss how these tools can be tailored to meet the unique needs of each developer and publisher.
For more information, connect and book meetings with Xsolla at the Devcom Developer Conference and Gamescom 2024, visit xsolla.events/gamescom24
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit xsolla.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807882430/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom